| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,800 | ₹3.05 1.66% | 4,250-2.85% |
| - | - | 4,900 | ₹0.05 0% | 1250% |
| 1250% | ₹720 0% | 5,000 | ₹4.1 0% | 3750% |
| - | - | 5,100 | ₹3.7 0% | 1,7500% |
| - | - | 5,200 | ₹4.7 -13.76% | 7,000-23.28% |
| 1250% | ₹472.75 0% | 5,300 | ₹7.7 -5.52% | 8,7507.69% |
| - | - | 5,400 | ₹13.5 -10.29% | 5,75031.42% |
| 1250% | ₹209.3 0% | 5,450 | ₹25 11.35% | 15,6250% |
| 5000% | ₹214.4 6.21% | 5,500 | ₹28.8 -15.29% | 24,375-2.01% |
| - | - | 5,550 | ₹36 -20.35% | 6,000-11.11% |
| 12,7502% | ₹104.1 -6.88% | 5,600 | ₹56 -4.02% | 14,6253.53% |
| 10,50013.51% | ₹80.35 -2.6% | 5,650 | ₹74.45 -13.68% | 9,12517.74% |
| 33,000-5.37% | ₹56 -7.74% | 5,700 | ₹109 -0.9% | 16,250-2.98% |
| 17,750-0.69% | ₹39.45 -6.29% | 5,750 | ₹172.9 0% | 10,6250% |
| 38,250-11.30% | ₹26.15 -16.32% | 5,800 | ₹150.75 1.27% | 16,6250% |
| 7,87516.66% | ₹20.8 -0.23% | 5,850 | ₹211.6 0% | 1,1250% |
| 39,125-2.49% | ₹12.3 -17.44% | 5,900 | ₹224.45 0% | 2500% |
| 37,8750.33% | ₹5.95 -25.15% | 6,000 | ₹350.75 0% | 2500% |
| 8,875-17.44% | ₹3.25 -42.98% | 6,100 | - | - |
| 4,5000% | ₹2.5 0% | 6,200 | ₹494.7 0% | 1250% |
| 62566.66% | ₹2.1 10.52% | 6,250 | - | - |
| 1,2500% | ₹3.5 0% | 6,300 | - | - |
| 2500% | ₹2.65 0% | 6,400 | - | - |
| 1,5000% | ₹17.65 0% | 6,500 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
